|
시장보고서
상품코드
2132456
항암제 시장 규모, 점유율, 동향 분석 보고서 : 약물 계열별, 암 유형별, 투여 경로별, 약물 유형별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)Oncology Drugs Market Size, Share & Trends Analysis Report By Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy), By Cancer Type, By Route of Administration, By Drug Type, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
항암제 시장 요약
세계의 항암제 시장 규모는 2025년에 2,576억 달러로 평가되며, 2026년 2,807억 달러에서 2033년까지 5,416억 달러로 확대될 것으로 예상되며, 2026년부터 2033년까지 CAGR 9.8%로 성장할 것으로 예측됩니다.
북미가 시장을 주도하고 있으며, 2025년에는 41.2%라는 가장 큰 매출 점유율을 차지했습니다. 전 세계 암 부담의 증가, 정밀 의학의 보급, 그리고 혁신적인 치료법에 대한 지속적인 투자로 인해 시장은 확대되고 있습니다.
면역요법, 표적 치료, 세포 치료의 활용 확대에 따라 여러 종양 유형에서 임상 결과가 개선되어 시장 성장을 뒷받침하고 있습니다. 바이오마커 검사 및 유전체 프로파일링의 발전으로 더욱 개인화된 치료 접근이 가능해졌으며, 한편 미충족 의료 수요를 충족하는 치료법에 대한 신속한 규제 심사 절차가 제품 출시를 가속화하고 있습니다. 신흥국의 의료비 지출 확대와 암 진단 및 치료에 대한 접근성 개선 또한 수요를 더욱 부추기고 있습니다.
그러나 고액의 치료비, 보험 환급 관련 과제, 그리고 제네릭 의약품 및 바이오시밀러 제품으로 인한 가격 압박 등이 계속해서 시장 동향에 영향을 미치고 있습니다. 복잡한 임상 개발 과정과 엄격한 규제 요건 또한 상용화 속도에 영향을 주고 있습니다. 이러한 과제들이 있음에도 불구하고, 지속적인 연구 협력, 암 임상시험의 증가, 그리고 동반진단의 보다 광범위한 통합을 통해 개발 파이프라인이 강화되어, 선진국 및 신흥국의 헬스케어 시장 모두에서 지속적인 시장 확대의 기회가 창출될 것으로 예상됩니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 항암제 시장 : 변수, 동향, 범위
제4장 항암제 시장 : 약물 계열별 비즈니스 분석
제5장 항암제 시장 : 암 종류별 비즈니스 분석
제6장 항암제 시장 : 투여 경로별 비즈니스 분석
제7장 항암제 시장 : 약물 유형별 비즈니스 분석
제8장 항암제 시장 : 유통 채널별 비즈니스 분석
제9장 항암제 시장 : 지역별 추정·동향 분석
제10장 경쟁 구도
KSM 26.09.28Oncology Drugs Market Summary
The global oncology drugs market size was valued at USD 257.6 billion in 2025 and is projected to grow from USD 280.7 billion in 2026 to USD 541.6 billion by 2033, at a CAGR of 9.8% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 41.2% in 2025. The market is expanding due to the rising global burden of cancer, increasing adoption of precision medicine, and continued investment in innovative therapies.
Growing use of immunotherapies, targeted therapies, and cell-based treatments is improving clinical outcomes across multiple tumor types and supporting market growth. Advances in biomarker testing and genomic profiling are enabling more personalized treatment approaches, while faster regulatory pathways for therapies addressing unmet medical needs are accelerating product launches. Expanding healthcare expenditure and improving access to cancer diagnosis and treatment in emerging economies are further supporting demand.
However, high treatment costs, reimbursement challenges, and pricing pressure from generic and biosimilar products continue to influence market performance. Complex clinical development processes and stringent regulatory requirements also affect the pace of commercialization. Despite these challenges, ongoing research collaborations, an increasing number of oncology clinical trials, and broader integration of companion diagnostics are expected to strengthen the development pipeline and create opportunities for sustained market expansion in both developed and emerging healthcare markets.
Global Oncology Drugs Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oncology drugs market report based on drug class, cancer type, route of administration, drug type, distribution channel, and region:
- Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
- Radiopharmaceuticals
- Cell & Gene Therapy
- Others
- Cancer Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Solid Tumors
- Hematologic Malignancies
- Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
- Oral
- Injectable
- Others
- Drug Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Branded
- Generic & Biosimilar
- Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Cancer Type
- 1.2.3. Route of Administration
- 1.2.4. Drug Type
- 1.2.5. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Oncology Drugs Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Oncology Drugs Market: Drug Class Business Analysis
- 4.1. Drug Class Market Share, 2025 & 2033
- 4.2. Drug Class Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
- 4.4. Chemotherapy
- 4.4.1. Chemotherapy Market, 2021 - 2033 (USD Billion)
- 4.5. Targeted Therapy
- 4.5.1. Targeted Therapy Market, 2021 - 2033 (USD Billion)
- 4.6. Immunotherapy
- 4.6.1. Immunotherapy Market, 2021 - 2033 (USD Billion)
- 4.7. Hormonal Therapy
- 4.7.1. Hormonal Therapy Market, 2021 - 2033 (USD Billion)
- 4.8. Radiopharmaceuticals
- 4.8.1. Radiopharmaceuticals Market, 2021 - 2033 (USD Billion)
- 4.9. Cell & Gene Therapy
- 4.9.1. Cell & Gene Therapy Market, 2021 - 2033 (USD Billion)
- 4.10. Others
- 4.10.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 5. Oncology Drugs Market: Cancer Type Business Analysis
- 5.1. Cancer Type Market Share, 2025 & 2033
- 5.2. Cancer Type Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Cancer Type, 2021 to 2033 (USD Billion)
- 5.4. Solid Tumors
- 5.4.1. Solid Tumors Market, 2021 - 2033 (USD Billion)
- 5.5. Hematologic Malignancies
- 5.5.1. Hematologic Malignancies Market, 2021 - 2033 (USD Billion)
Chapter 6. Oncology Drugs Market: Route of Administration Business Analysis
- 6.1. Route of Administration Market Share, 2025 & 2033
- 6.2. Route of Administration Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
- 6.4. Oral
- 6.4.1. Oral Market, 2021 - 2033 (USD Billion)
- 6.5. Injectable
- 6.5.1. Injectable Market, 2021 - 2033 (USD Billion)
- 6.6. Others
- 6.6.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 7. Oncology Drugs Market: Drug Type Business Analysis
- 7.1. Drug Type Market Share, 2025 & 2033
- 7.2. Drug Type Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Billion)
- 7.4. Branded
- 7.4.1. Branded Market, 2021 - 2033 (USD Billion)
- 7.5. Generic & Biosimilar
- 7.5.1. Generic & Biosimilar Market, 2021 - 2033 (USD Billion)
Chapter 8. Oncology Drugs Market: Distribution Channel Business Analysis
- 8.1. Distribution Channel Market Share, 2025 & 2033
- 8.2. Distribution Channel Segment Dashboard
- 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
- 8.4. Hospital Pharmacies
- 8.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
- 8.5. Retail Pharmacies
- 8.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
- 8.6. Online Pharmacies
- 8.6.1. Online Pharmacies Market, 2021 - 2033 (USD Billion)
Chapter 9. Oncology Drugs Market: Regional Estimates & Trend Analysis
- 9.1. Regional Market Share Analysis, 2025 & 2033
- 9.2. Regional Market Dashboard
- 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 9.4. North America
- 9.4.1. North America Oncology Drugs Market Estimates and Forecasts, By Country, 2021-2033 (USD Billion)
- 9.4.2. U.S.
- 9.4.2.1. Key Country Dynamics
- 9.4.2.2. Target Disease Prevalence
- 9.4.2.3. Regulatory Framework
- 9.4.2.4. Reimbursement Framework
- 9.4.2.5. U.S. Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.4.3. Canada
- 9.4.3.1. Key Country Dynamics
- 9.4.3.2. Target Disease Prevalence
- 9.4.3.3. Regulatory Framework
- 9.4.3.4. Reimbursement Framework
- 9.4.3.5. Canada Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.4.4. Mexico
- 9.4.4.1. Key Country Dynamics
- 9.4.4.2. Target Disease Prevalence
- 9.4.4.3. Regulatory Framework
- 9.4.4.4. Reimbursement Framework
- 9.4.4.5. Mexico Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.5. Europe
- 9.5.1. Europe Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.5.2. UK
- 9.5.2.1. Key Country Dynamics
- 9.5.2.2. Target Disease Prevalence
- 9.5.2.3. Regulatory Framework
- 9.5.2.4. Reimbursement Framework
- 9.5.2.5. UK Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.5.3. Germany
- 9.5.3.1. Key Country Dynamics
- 9.5.3.2. Target Disease Prevalence
- 9.5.3.3. Regulatory Framework
- 9.5.3.4. Reimbursement Framework
- 9.5.3.5. Germany Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.5.4. France
- 9.5.4.1. Key Country Dynamics
- 9.5.4.2. Target Disease Prevalence
- 9.5.4.3. Regulatory Framework
- 9.5.4.4. Reimbursement Framework
- 9.5.4.5. France Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.5.5. Italy
- 9.5.5.1. Key Country Dynamics
- 9.5.5.2. Target Disease Prevalence
- 9.5.5.3. Regulatory Framework
- 9.5.5.4. Reimbursement Framework
- 9.5.5.5. Italy Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.5.6. Spain
- 9.5.6.1. Key Country Dynamics
- 9.5.6.2. Target Disease Prevalence
- 9.5.6.3. Regulatory Framework
- 9.5.6.4. Reimbursement Framework
- 9.5.6.5. Spain Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.5.7. Denmark
- 9.5.7.1. Key Country Dynamics
- 9.5.7.2. Target Disease Prevalence
- 9.5.7.3. Regulatory Framework
- 9.5.7.4. Reimbursement Framework
- 9.5.7.5. Denmark Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.5.8. Sweden
- 9.5.8.1. Key Country Dynamics
- 9.5.8.2. Target Disease Prevalence
- 9.5.8.3. Regulatory Framework
- 9.5.8.4. Reimbursement Framework
- 9.5.8.5. Sweden Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.5.9. Norway
- 9.5.9.1. Key Country Dynamics
- 9.5.9.2. Target Disease Prevalence
- 9.5.9.3. Regulatory Framework
- 9.5.9.4. Reimbursement Framework
- 9.5.9.5. Norway Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.6. Asia Pacific
- 9.6.1. Asia Pacific Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.6.2. Japan
- 9.6.2.1. Key Country Dynamics
- 9.6.2.2. Target Disease Prevalence
- 9.6.2.3. Regulatory Framework
- 9.6.2.4. Reimbursement Framework
- 9.6.2.5. Japan Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.6.3. China
- 9.6.3.1. Key Country Dynamics
- 9.6.3.2. Target Disease Prevalence
- 9.6.3.3. Regulatory Framework
- 9.6.3.4. Reimbursement Framework
- 9.6.3.5. China Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.6.4. India
- 9.6.4.1. Key Country Dynamics
- 9.6.4.2. Target Disease Prevalence
- 9.6.4.3. Regulatory Framework
- 9.6.4.4. Reimbursement Framework
- 9.6.4.5. India Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.6.5. Australia
- 9.6.5.1. Key Country Dynamics
- 9.6.5.2. Target Disease Prevalence
- 9.6.5.3. Regulatory Framework
- 9.6.5.4. Reimbursement Framework
- 9.6.5.5. Australia Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.6.6. South Korea
- 9.6.6.1. Key Country Dynamics
- 9.6.6.2. Target Disease Prevalence
- 9.6.6.3. Regulatory Framework
- 9.6.6.4. Reimbursement Framework
- 9.6.6.5. South Korea Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.6.7. Thailand
- 9.6.7.1. Key Country Dynamics
- 9.6.7.2. Target Disease Prevalence
- 9.6.7.3. Regulatory Framework
- 9.6.7.4. Reimbursement Framework
- 9.6.7.5. Thailand Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.7. Latin America
- 9.7.1. Latin America Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.7.2. Brazil
- 9.7.2.1. Key Country Dynamics
- 9.7.2.2. Target Disease Prevalence
- 9.7.2.3. Regulatory Framework
- 9.7.2.4. Reimbursement Framework
- 9.7.2.5. Brazil Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.7.3. Argentina
- 9.7.3.1. Key Country Dynamics
- 9.7.3.2. Target Disease Prevalence
- 9.7.3.3. Regulatory Framework
- 9.7.3.4. Reimbursement Framework
- 9.7.3.5. Argentina Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.8. Middle East and Africa
- 9.8.1. Middle East and Africa Oncology Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 9.8.2. South Africa
- 9.8.2.1. Key Country Dynamics
- 9.8.2.2. Target Disease Prevalence
- 9.8.2.3. Regulatory Framework
- 9.8.2.4. Reimbursement Framework
- 9.8.2.5. South Africa Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.8.3. Saudi Arabia
- 9.8.3.1. Key Country Dynamics
- 9.8.3.2. Target Disease Prevalence
- 9.8.3.3. Regulatory Framework
- 9.8.3.4. Reimbursement Framework
- 9.8.3.5. Saudi Arabia Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.8.4. UAE
- 9.8.4.1. Key Country Dynamics
- 9.8.4.2. Target Disease Prevalence
- 9.8.4.3. Regulatory Framework
- 9.8.4.4. Reimbursement Framework
- 9.8.4.5. UAE Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
- 9.8.5. Kuwait
- 9.8.5.1. Key Country Dynamics
- 9.8.5.2. Target Disease Prevalence
- 9.8.5.3. Regulatory Framework
- 9.8.5.4. Reimbursement Framework
- 9.8.5.5. Kuwait Oncology Drugs Market Estimates and Forecasts, 2021-2033 (USD Billion)
Chapter 10. Competitive Landscape
- 10.1. Participant Overview
- 10.2. Company Market Position Analysis
- 10.3. Company Categorization
- 10.4. Strategy Mapping
- 10.5. Company Profiles/Listing
- 10.5.1. Roche Holding AG
- 10.5.1.1. Overview
- 10.5.1.2. Financial Performance
- 10.5.1.3. Product Benchmarking
- 10.5.1.4. Strategic Initiatives
- 10.5.2. Merck & Co., Inc.
- 10.5.2.1. Overview
- 10.5.2.2. Financial Performance
- 10.5.2.3. Product Benchmarking
- 10.5.2.4. Strategic Initiatives
- 10.5.3. AstraZeneca PLC
- 10.5.3.1. Overview
- 10.5.3.2. Financial Performance
- 10.5.3.3. Product Benchmarking
- 10.5.3.4. Strategic Initiatives
- 10.5.4. Bristol Myers Squibb
- 10.5.4.1. Overview
- 10.5.4.2. Financial Performance
- 10.5.4.3. Product Benchmarking
- 10.5.4.4. Strategic Initiatives
- 10.5.5. Pfizer Inc.
- 10.5.5.1. Overview
- 10.5.5.2. Financial Performance
- 10.5.5.3. Product Benchmarking
- 10.5.5.4. Strategic Initiatives
- 10.5.6. Novartis AG
- 10.5.6.1. Overview
- 10.5.6.2. Financial Performance
- 10.5.6.3. Product Benchmarking
- 10.5.6.4. Strategic Initiatives
- 10.5.7. Johnson & Johnson
- 10.5.7.1. Overview
- 10.5.7.2. Financial Performance
- 10.5.7.3. Product Benchmarking
- 10.5.7.4. Strategic Initiatives
- 10.5.8. Eli Lilly and Company
- 10.5.8.1. Overview
- 10.5.8.2. Financial Performance
- 10.5.8.3. Product Benchmarking
- 10.5.8.4. Strategic Initiatives
- 10.5.9. GSK plc
- 10.5.9.1. Overview
- 10.5.9.2. Financial Performance
- 10.5.9.3. Product Benchmarking
- 10.5.9.4. Strategic Initiatives
- 10.5.10. Amgen Inc.
- 10.5.10.1. Overview
- 10.5.10.2. Financial Performance
- 10.5.10.3. Product Benchmarking
- 10.5.10.4. Strategic Initiatives
- 10.5.1. Roche Holding AG
